A 15-year follow-up study of patients with panic disorder - 01/01/03
Sven Andersch * , Jerker Hetta*Corresponding author. Present address: Psychiatric Outpatient Centre, Sahlgrenska University Hospital, Mellanvardsteamet, Lilla Badhusgatan 2, 41121 Gothenburg, Sweden.
Voir les affiliationspages | 8 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Résumé |
Background. - Panic disorder (PD) is generally regarded as a chronic condition with considerable variation in severity of symptoms.
Aims. - To describe the long-term outcome of naturalistically treated PD.
Methods. - Fifty-five outpatients with PD, who participated in a placebo-controlled drug trial of the efficacy of alprazolam and imipramine 15 years ago were reassessed with the same instruments used in the original study.
Results. - Complete recovery (no panic attacks and no longer on medication during the last 10 years) was seen in 18% of patients, and an additional 13% recovered but were still on medication. Fifty-one percent experienced recurrent anxiety attacks whereas 18% still met diagnostic criteria for PD. The incidence of agoraphobia decreased from 69% to 20%. Patients with agoraphobia at admission tended to have a poorer long-term outcome according to daily functioning compared with patients without agoraphobia at admission, although both groups reported improved daily functioning at follow-up. Maintenance medication was common. No benzodiazepine abuse was reported.
Conclusion. - PD has a favourable outcome in a substantial proportion of patients. However, the illness is chronic and needs treatment. The short-term treatment given in the drug trial had no influence on the long-term outcome.
Mots clés : Anxiety disorder ; Panic disorder ; Agoraphobia ; Long-term outcome.
Plan
Vol 18 - N° 8
P. 401-408 - décembre 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?